Paula Cobb
Directeur/Membre du Conseil chez PROTHENA CORPORATION PLC
Fortune : - $ au 30/04/2024
Profil
Ms. Paula K.
Cobb is an Independent Director at Prothena Corp.
Plc.
She is on the Board of Directors at Prothena Corp.
Plc and NightstaRx Ltd.
Ms. Cobb was previously employed as a Chief Business Officer by Affinia Therapeutics, Inc., an Independent Non-Executive Director by Nightstar Therapeutics Plc, a Chief Operating Officer by Decibel Therapeutics, Inc., and a Senior Vice President-Rare Disease Group by Biogen, Inc. She received her undergraduate degree from Amherst College and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PROTHENA CORP. PLC
-.--% | 15/05/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Paula Cobb
| Sociétés | Poste | Début |
|---|---|---|
| PROTHENA CORPORATION PLC | Directeur/Membre du Conseil | 01/07/2019 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Paula Cobb
| Sociétés | Poste | Fin |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/01/2023 |
| DECIBEL THERAPEUTICS, INC. | Directeur des opérations | 01/12/2019 |
| NIGHTSTAR THERAPEUTICS PLC | Directeur/Membre du Conseil | 07/06/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2016 |
Formation de Paula Cobb
| Amherst College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| PROTHENA CORPORATION PLC | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |